Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids

Raymond Hohl, D. M. Pogatchnik, K. Lewis-Tibesar, D. F. Wiemer

Research output: Contribution to journalArticle

Abstract

Farnesyl protein transferase (FPTase) is an attractive target for anti-RAS therapies. We have synthesized a series of isoprenoid phosphonic acids to characterize the structural requirements for FPTase inhibition. Analogues were tested for mammalian FPTase and squalene synthase inhibitory activities in enzyme and intact cell assays. E,E-α-hydroxyfarnesylphosphonate inhibits FPTase with a 50% inhibitory concentration (IC50) of 30 nM whereas the Z,E-isomer is inactive. In human-derived THP-1 myeloid and RPMI-8402 lymphoid leukemia cells 100 μM E,E-α-hydroxyfarnesylphosphonate induces accumulation of unmodified RAS proteins and the Z,E-isomer is inactive. In contrast, squalene synthase is only minimally inhibited by the active E,E-isomer with a reduction of squalene synthase activity to 80% of control occurring at 1 μM levels. Cholesterol synthesis in intact cells is not decreased with concentrations as high as 200 μM of the E,E-isomer. We conclude from these studies that there is differential inhibition of FPTase and squalene synthase by E,E-α-hydroxyfamesylphosphonate thus supporting the concept that isoprenoid phosphonic acids may have eventual clinical utility as anti-RAS therapies.

Original languageEnglish (US)
Pages (from-to)144
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997

Fingerprint

Phosphorous Acids
Farnesyl-Diphosphate Farnesyltransferase
Terpenes
Transferases
Proteins
Inhibitory Concentration 50
Lymphoid Leukemia
Cholesterol
Lymphocytes
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{73d30e925c68485c90e20ddb3fe9c676,
title = "Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids",
abstract = "Farnesyl protein transferase (FPTase) is an attractive target for anti-RAS therapies. We have synthesized a series of isoprenoid phosphonic acids to characterize the structural requirements for FPTase inhibition. Analogues were tested for mammalian FPTase and squalene synthase inhibitory activities in enzyme and intact cell assays. E,E-α-hydroxyfarnesylphosphonate inhibits FPTase with a 50{\%} inhibitory concentration (IC50) of 30 nM whereas the Z,E-isomer is inactive. In human-derived THP-1 myeloid and RPMI-8402 lymphoid leukemia cells 100 μM E,E-α-hydroxyfarnesylphosphonate induces accumulation of unmodified RAS proteins and the Z,E-isomer is inactive. In contrast, squalene synthase is only minimally inhibited by the active E,E-isomer with a reduction of squalene synthase activity to 80{\%} of control occurring at 1 μM levels. Cholesterol synthesis in intact cells is not decreased with concentrations as high as 200 μM of the E,E-isomer. We conclude from these studies that there is differential inhibition of FPTase and squalene synthase by E,E-α-hydroxyfamesylphosphonate thus supporting the concept that isoprenoid phosphonic acids may have eventual clinical utility as anti-RAS therapies.",
author = "Raymond Hohl and Pogatchnik, {D. M.} and K. Lewis-Tibesar and Wiemer, {D. F.}",
year = "1997",
language = "English (US)",
volume = "61",
pages = "144",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids. / Hohl, Raymond; Pogatchnik, D. M.; Lewis-Tibesar, K.; Wiemer, D. F.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 144.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids

AU - Hohl, Raymond

AU - Pogatchnik, D. M.

AU - Lewis-Tibesar, K.

AU - Wiemer, D. F.

PY - 1997

Y1 - 1997

N2 - Farnesyl protein transferase (FPTase) is an attractive target for anti-RAS therapies. We have synthesized a series of isoprenoid phosphonic acids to characterize the structural requirements for FPTase inhibition. Analogues were tested for mammalian FPTase and squalene synthase inhibitory activities in enzyme and intact cell assays. E,E-α-hydroxyfarnesylphosphonate inhibits FPTase with a 50% inhibitory concentration (IC50) of 30 nM whereas the Z,E-isomer is inactive. In human-derived THP-1 myeloid and RPMI-8402 lymphoid leukemia cells 100 μM E,E-α-hydroxyfarnesylphosphonate induces accumulation of unmodified RAS proteins and the Z,E-isomer is inactive. In contrast, squalene synthase is only minimally inhibited by the active E,E-isomer with a reduction of squalene synthase activity to 80% of control occurring at 1 μM levels. Cholesterol synthesis in intact cells is not decreased with concentrations as high as 200 μM of the E,E-isomer. We conclude from these studies that there is differential inhibition of FPTase and squalene synthase by E,E-α-hydroxyfamesylphosphonate thus supporting the concept that isoprenoid phosphonic acids may have eventual clinical utility as anti-RAS therapies.

AB - Farnesyl protein transferase (FPTase) is an attractive target for anti-RAS therapies. We have synthesized a series of isoprenoid phosphonic acids to characterize the structural requirements for FPTase inhibition. Analogues were tested for mammalian FPTase and squalene synthase inhibitory activities in enzyme and intact cell assays. E,E-α-hydroxyfarnesylphosphonate inhibits FPTase with a 50% inhibitory concentration (IC50) of 30 nM whereas the Z,E-isomer is inactive. In human-derived THP-1 myeloid and RPMI-8402 lymphoid leukemia cells 100 μM E,E-α-hydroxyfarnesylphosphonate induces accumulation of unmodified RAS proteins and the Z,E-isomer is inactive. In contrast, squalene synthase is only minimally inhibited by the active E,E-isomer with a reduction of squalene synthase activity to 80% of control occurring at 1 μM levels. Cholesterol synthesis in intact cells is not decreased with concentrations as high as 200 μM of the E,E-isomer. We conclude from these studies that there is differential inhibition of FPTase and squalene synthase by E,E-α-hydroxyfamesylphosphonate thus supporting the concept that isoprenoid phosphonic acids may have eventual clinical utility as anti-RAS therapies.

UR - http://www.scopus.com/inward/record.url?scp=33748983802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748983802&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748983802

VL - 61

SP - 144

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -